CN101193637A - 作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物 - Google Patents

作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物 Download PDF

Info

Publication number
CN101193637A
CN101193637A CNA2006800025587A CN200680002558A CN101193637A CN 101193637 A CN101193637 A CN 101193637A CN A2006800025587 A CNA2006800025587 A CN A2006800025587A CN 200680002558 A CN200680002558 A CN 200680002558A CN 101193637 A CN101193637 A CN 101193637A
Authority
CN
China
Prior art keywords
alkyl
treatment
aryl
cycloalkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800025587A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·科尔曼
G·D·哈特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101193637A publication Critical patent/CN101193637A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800025587A 2005-01-19 2006-01-13 作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物 Pending CN101193637A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64490705P 2005-01-19 2005-01-19
US60/644,907 2005-01-19

Publications (1)

Publication Number Publication Date
CN101193637A true CN101193637A (zh) 2008-06-04

Family

ID=36692759

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800025587A Pending CN101193637A (zh) 2005-01-19 2006-01-13 作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物

Country Status (7)

Country Link
US (1) US7632839B2 (US07794700-20100914-C00152.png)
EP (1) EP1855664A4 (US07794700-20100914-C00152.png)
JP (1) JP2008527039A (US07794700-20100914-C00152.png)
CN (1) CN101193637A (US07794700-20100914-C00152.png)
AU (1) AU2006206652A1 (US07794700-20100914-C00152.png)
CA (1) CA2595130A1 (US07794700-20100914-C00152.png)
WO (1) WO2006078575A2 (US07794700-20100914-C00152.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573838A (zh) * 2009-10-06 2012-07-11 拜耳制药股份公司 氟取代的3,5-二氰基-4-(1h-吲唑-5-基)-2,6-二甲基-1,4-二氢吡啶衍生物和其使用方法
CN107904201A (zh) * 2008-10-31 2018-04-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2483627A1 (en) * 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107904201A (zh) * 2008-10-31 2018-04-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
CN102573838A (zh) * 2009-10-06 2012-07-11 拜耳制药股份公司 氟取代的3,5-二氰基-4-(1h-吲唑-5-基)-2,6-二甲基-1,4-二氢吡啶衍生物和其使用方法
CN102573838B (zh) * 2009-10-06 2014-09-24 拜耳知识产权有限责任公司 氟取代的3,5-二氰基-4-(1h-吲唑-5-基)-2,6-二甲基-1,4-二氢吡啶衍生物和其使用方法

Also Published As

Publication number Publication date
AU2006206652A1 (en) 2006-07-27
JP2008527039A (ja) 2008-07-24
CA2595130A1 (en) 2006-07-27
EP1855664A2 (en) 2007-11-21
WO2006078575A3 (en) 2007-12-13
US20080139586A1 (en) 2008-06-12
WO2006078575A2 (en) 2006-07-27
US7632839B2 (en) 2009-12-15
EP1855664A4 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CN101193637A (zh) 作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物
CN100548296C (zh) 有丝分裂驱动蛋白抑制剂
CN101107253A (zh) 有丝分裂驱动蛋白抑制剂
CN101084194A (zh) 有丝分裂驱动蛋白抑制剂
CN101106998A (zh) 有丝分裂驱动蛋白抑制剂
CN101155583B (zh) 有丝分裂驱动蛋白的抑制剂
CN101115745A (zh) 有丝分裂驱动蛋白抑制剂
CN101005837A (zh) 有丝分裂驱动蛋白抑制剂
CN1980662A (zh) 有丝分裂驱动蛋白抑制剂
JP2007517071A (ja) 有糸分裂キネシン阻害剤
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
CN1980911A (zh) 有丝分裂驱动蛋白抑制剂
CN101142183A (zh) 有丝分裂驱动蛋白抑制剂
JP2008510012A (ja) 有糸分裂キネシン阻害剤
JP2007518711A (ja) 有糸分裂キネシン阻害剤
US20070149553A1 (en) Mitotic kinesin inhibitors
JP2008505090A (ja) 有糸分裂キネシン阻害剤のプロドラッグ
CN1980663A (zh) 有丝分裂驱动蛋白抑制剂的前体药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080604